MSH|^~\&|LAB|RCH|||201911141441||ORU^R01|4105754|D|2.3|||AL|NE
PID|1||RC00007229|RC7037|LABTEST^ALMONDTHINS^||20130120|F||||||||||RC000622/19|9875495454
OBR|1|35155^LAB|00026997^1311:C00024R^LAB^131119:C24^35155|522.2490^BHCG^Beta-HCG^^^21198-7||201911131243|201911131000|||||||201911131243||||||||||LAB|F||||
NTE|1||>dCG5 limit
OBX|1|ST|522.2510^BHCG R^Beta-HCG^^21198-7^21198-7|1|349466^^Y|IU/L|<10|H||A^S|F|||201911141441
NTE|1||Reference Intervals, (guideline only) FOR B-HCG (U/L):
NTE|2||
NTE|3||Male or non-pregnant female            Less than 10
NTE|4||Pregnant female:
NTE|5||Time after LMP:        Expected beta-HCG range(WHO 3rd IRP):
NTE|6||4th  week                               25 - 426
NTE|7||5th  week                               25 - 7340
NTE|8||6th  week                             1080 - 56500
NTE|9||10th week                            54100 - 288000
NTE|10||18th week                             8910 - 66000
NTE|11||31st week                             5310 - 27400
NTE|12||*************************NOTE*******************************
NTE|13||Occasional patients with heterophile antibodies may have
NTE|14||erroneous BHCG results. Serum BHCG should not be used for
NTE|15||routine pregnancy tests. Urine does not contain heterophile
NTE|16||antibodies and may be used where apparent discrepant results
NTE|17||are experienced.
NTE|18||Method:Beckman Access/DxI